Topotecan for Advanced Ovarian Cancer
Author Information
Author(s): Gore M, Rustin G, Schüller J, Lane S R, Hearn S, Beckman R A, Ross G
Primary Institution: Royal Marsden Hospital
Hypothesis
Can topotecan administered as a 21-day infusion effectively treat recurrent ovarian cancer?
Conclusion
Topotecan as a 21-day infusion showed a partial response in 8.6% of patients with recurrent ovarian cancer.
Supporting Evidence
- 3 patients (8.6%) had a partial response to treatment.
- Median time to response was 8.1 weeks.
- Median duration of response was 17.6 weeks.
- Median time to progression was 16.1 weeks.
- Median survival was 43.6 weeks.
- The principal toxicity was myelosuppression.
- Grade 4 neutropenia occurred in only 8.8% of patients.
- Non-haematological toxicity was generally mild.
Takeaway
Doctors tested a medicine called topotecan to see if it helps people with a type of cancer called ovarian cancer, and a few people got better.
Methodology
Patients received topotecan 0.4 mg/m2/day as a 21-day infusion every 28 days after failing first-line therapy.
Limitations
Response rates may vary due to differences in patient demographics.
Participant Demographics
Patients had previously failed a platinum-based regimen and were only permitted one prior treatment.
Statistical Information
Confidence Interval
95% CI 1.8%, 23.1%
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website